Abstract
In this study, high-risk patients with hypertrophic cardiomyopathy were treated with an implantable defibrillator. Long-term follow-up analysis showed the efficacy of implantable defibrillator therapy, with patients having an appropriate device intervention at a rate of 11%/year, thereby preventing sudden death in an Australian population.
Publication types
- Evaluation Study
- Research Support, Non-U.S. Gov't
MeSH terms
- Adrenergic beta-Antagonists / therapeutic use
- Adult
- Australia
- Cardiomyopathy, Hypertrophic / epidemiology
- Cardiomyopathy, Hypertrophic / therapy*
- Defibrillators, Implantable*
- Follow-Up Studies
- Humans
- Hypertrophy, Left Ventricular / epidemiology
- Hypertrophy, Left Ventricular / therapy
- Middle Aged
- Postoperative Complications / epidemiology
- Postoperative Complications / etiology
- Risk Factors
- Sotalol / therapeutic use
- Time
- Treatment Outcome
Substances
- Adrenergic beta-Antagonists
- Sotalol